Correlation Between Hookipa Pharma and SAB Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Hookipa Pharma and SAB Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hookipa Pharma and SAB Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Hookipa Pharma and SAB Biotherapeutics, you can compare the effects of market volatilities on Hookipa Pharma and SAB Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hookipa Pharma with a short position of SAB Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hookipa Pharma and SAB Biotherapeutics.

Diversification Opportunities for Hookipa Pharma and SAB Biotherapeutics

0.7

Correlation Coefficient

Hookipa Pharma  SAB Biotherapeutics

Poor diversification

The 3 months correlation between Hookipa and SAB is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Hookipa Pharma and SAB Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SAB Biotherapeutics and Hookipa Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hookipa Pharma are associated (or correlated) with SAB Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SAB Biotherapeutics has no effect on the direction of Hookipa Pharma i.e., Hookipa Pharma and SAB Biotherapeutics go up and down completely randomly.

Pair Corralation between Hookipa Pharma and SAB Biotherapeutics

Given the investment horizon of 90 days Hookipa Pharma is expected to generate 0.59 times more return on investment than SAB Biotherapeutics. However, Hookipa Pharma is 1.7 times less risky than SAB Biotherapeutics. It trades about -0.14 of its potential returns per unit of risk. SAB Biotherapeutics is currently generating about -0.13 per unit of risk. If you would invest  194.00  in Hookipa Pharma on December 27, 2024 and sell it today you would lose (76.70) from holding Hookipa Pharma or give up 39.54% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	98.36%
Values	Daily Returns

Hookipa Pharma  vs.  SAB Biotherapeutics

Hookipa Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Hookipa Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

SAB Biotherapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days SAB Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Hookipa Pharma and SAB Biotherapeutics

The main advantage of trading using opposite Hookipa Pharma and SAB Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hookipa Pharma position performs unexpectedly, SAB Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will offset losses from the drop in SAB Biotherapeutics' long position.

The idea behind Hookipa Pharma and SAB Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.